Patel Mona Chetan 4

What Happened

• Mona Chetan Patel, a director of Envoy Medical, reported acquiring a total of 812,500 shares on 2026-02-12. The reported activity includes a cash purchase of 312,500 shares at $0.40 each (total $125,000) plus two derivative-based acquisitions of 187,500 and 312,500 shares at $0.00 (total 500,000 derivative shares).
• The cash purchase is a straightforward open-market/private purchase (transaction code P) and is a buy signal. The $0.00 entries are derivative transactions (warrants/options or similar instruments) — these did not require cash payment at the time of reporting but are subject to the terms described in the footnotes.

Key Details

• Transaction date: February 12, 2026.
• Prices and totals: 312,500 shares @ $0.40 = $125,000 (cash purchase); 187,500 and 312,500 shares @ $0.00 = $0 (derivative acquisitions). Total shares acquired: 812,500.
• Shares owned after the transaction: not provided in the material you supplied.
• Footnotes of note:
  • F1: Some options vest over time (initial tranche and monthly pro rata vesting).
  • F2: Certain instruments are exercisable only upon shareholder approval to issue Class A shares.
  • F3/F4: Series A-1 and A-2 warrants include expiration conditions tied to FDA filing/approval milestones for the Acclaim CI Device.
• Filing timeliness: Report filed 2026-02-17 for transactions dated 2026-02-12. This filing appears to be within the SEC’s business-day window (no late filing flag indicated).

Context

• The derivative entries reflect acquisition via warrants/options or similar instruments rather than additional cash purchases. Such derivative shares may be subject to vesting, shareholder approval, or exercise/expiration conditions (see footnotes).
• Purchases by company insiders can be informative to investors because they increase the insider’s ownership; derivative acquisitions can be more complex and depend on future approvals or vesting schedules. This summary is factual and does not speculate on the insider’s motivation.